Tubize-Fin
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. It engages in discovering and developing treatments for patients suffering from serious illnesses that affects immune system or central nervous system. The company was incorporated in 1928 and is based in Brussels, Belgium.
Tubize-Fin (TUB) - Net Assets
Latest net assets as of June 2025: €1.94 Billion EUR
Based on the latest financial reports, Tubize-Fin (TUB) has net assets worth €1.94 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.94 Billion) and total liabilities (€367.02K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.94 Billion |
| % of Total Assets | 99.98% |
| Annual Growth Rate | 6.11% |
| 5-Year Change | -34.1% |
| 10-Year Change | -5.49% |
| Growth Volatility | 18.19 |
Tubize-Fin - Net Assets Trend (2000–2024)
This chart illustrates how Tubize-Fin's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tubize-Fin (2000–2024)
The table below shows the annual net assets of Tubize-Fin from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.84 Billion | +2.44% |
| 2023-12-31 | €1.80 Billion | +2.57% |
| 2022-12-31 | €1.75 Billion | -46.05% |
| 2021-12-31 | €3.25 Billion | +16.25% |
| 2020-12-31 | €2.79 Billion | +4.83% |
| 2019-12-31 | €2.66 Billion | +13.88% |
| 2018-12-31 | €2.34 Billion | +10.58% |
| 2017-12-31 | €2.12 Billion | +8.08% |
| 2016-12-31 | €1.96 Billion | +0.53% |
| 2015-12-31 | €1.95 Billion | +20.07% |
| 2014-12-31 | €1.62 Billion | +4.54% |
| 2013-12-31 | €1.55 Billion | +3.96% |
| 2012-12-31 | €1.49 Billion | -3.61% |
| 2011-12-31 | €1.55 Billion | +7.23% |
| 2010-12-31 | €1.44 Billion | +6.40% |
| 2009-12-31 | €1.36 Billion | +13.53% |
| 2008-12-31 | €1.20 Billion | -5.22% |
| 2007-12-31 | €1.26 Billion | -6.93% |
| 2006-12-31 | €1.36 Billion | +50.33% |
| 2005-12-31 | €901.39 Million | +52.12% |
| 2004-12-31 | €592.56 Million | -6.67% |
| 2003-12-31 | €634.91 Million | +10.10% |
| 2002-12-31 | €576.65 Million | +11.23% |
| 2001-12-31 | €518.43 Million | +16.91% |
| 2000-12-31 | €443.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tubize-Fin's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 13505082600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €135.05 Million | 7.34% |
| Common Stock | €235.00 Million | 12.77% |
| Other Comprehensive Income | €1.47 Billion | 79.83% |
| Other Components | €1.22 Million | 0.07% |
| Total Equity | €1.84 Billion | 100.00% |
Tubize-Fin Competitors by Market Cap
The table below lists competitors of Tubize-Fin ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ho Chi Minh City Development Joint Stock Commercial Bank
VN:HDB
|
$4.29 Billion |
|
Contact Energy Ltd
AU:CEN
|
$4.29 Billion |
|
ATLANTIC UNION BANKS.DL 2
F:UIO
|
$4.29 Billion |
|
PT Bayan Resources Tbk
F:BNB
|
$4.29 Billion |
|
Shenzhen Woer Heat-Shrinkable Material Co Ltd
SHE:002130
|
$4.28 Billion |
|
Edenred SA
PA:EDEN
|
$4.27 Billion |
|
Urban Outfitters Inc
NASDAQ:URBN
|
$4.27 Billion |
|
Inari Medical Inc
NASDAQ:NARI
|
$4.27 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tubize-Fin's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,796,594,299 to 1,840,405,526, a change of 43,811,227 (2.4%).
- Net income of 90,104,329 contributed positively to equity growth.
- Dividend payments of 43,176,000 reduced retained earnings.
- Other comprehensive income increased equity by 22,730,708.
- Other factors decreased equity by 25,847,810.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €90.10 Million | +4.9% |
| Dividends Paid | €43.18 Million | -2.35% |
| Other Comprehensive Income | €22.73 Million | +1.24% |
| Other Changes | €-25.85 Million | -1.4% |
| Total Change | €- | 2.44% |
Book Value vs Market Value Analysis
This analysis compares Tubize-Fin's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.26x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 27.87x to 5.26x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | €7.80 | €217.50 | x |
| 2004-12-31 | €13.02 | €217.50 | x |
| 2005-12-31 | €20.21 | €217.50 | x |
| 2006-12-31 | €30.38 | €217.50 | x |
| 2007-12-31 | €28.27 | €217.50 | x |
| 2008-12-31 | €26.80 | €217.50 | x |
| 2009-12-31 | €30.42 | €217.50 | x |
| 2010-12-31 | €32.37 | €217.50 | x |
| 2011-12-31 | €34.71 | €217.50 | x |
| 2012-12-31 | €33.46 | €217.50 | x |
| 2013-12-31 | €34.78 | €217.50 | x |
| 2014-12-31 | €36.25 | €217.50 | x |
| 2015-12-31 | €43.71 | €217.50 | x |
| 2016-12-31 | €43.97 | €217.50 | x |
| 2017-12-31 | €47.50 | €217.50 | x |
| 2018-12-31 | €52.52 | €217.50 | x |
| 2019-12-31 | €418.02 | €217.50 | x |
| 2020-12-31 | €62.74 | €217.50 | x |
| 2021-12-31 | €72.94 | €217.50 | x |
| 2022-12-31 | €39.35 | €217.50 | x |
| 2023-12-31 | €40.36 | €217.50 | x |
| 2024-12-31 | €41.35 | €217.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tubize-Fin utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 679673.60%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (4.90%) is below the historical average (11.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 47.23% | 54422.12% | 0.00x | 3.16x | €93.09 Million |
| 2004 | 20.91% | 6195350.00% | 0.00x | 1.21x | €64.65 Million |
| 2005 | 32.60% | 96.36% | 0.30x | 1.13x | €203.72 Million |
| 2006 | 35.22% | 303.77% | 0.10x | 1.18x | €341.77 Million |
| 2007 | 3.13% | 67.48% | 0.03x | 1.33x | €-86.58 Million |
| 2008 | -0.08% | -5.70% | 0.01x | 1.33x | €-120.44 Million |
| 2009 | 12.03% | 90.97% | 0.10x | 1.27x | €27.60 Million |
| 2010 | 1.45% | 55.99% | 0.02x | 1.24x | €-123.53 Million |
| 2011 | 4.18% | 76.35% | 0.05x | 1.21x | €-90.15 Million |
| 2012 | 5.21% | 83.87% | 0.05x | 1.20x | €-71.43 Million |
| 2013 | 3.98% | 81.40% | 0.04x | 1.16x | €-93.44 Million |
| 2014 | 3.75% | 84.99% | 0.04x | 1.13x | €-101.34 Million |
| 2015 | 10.91% | 21252600.00% | 0.00x | 1.16x | €17.79 Million |
| 2016 | 9.26% | 59995.36% | 0.00x | 1.14x | €-14.57 Million |
| 2017 | 13.52% | 105.03% | 0.12x | 1.09x | €74.37 Million |
| 2018 | 12.19% | 98.93% | 0.12x | 1.06x | €51.20 Million |
| 2019 | 10.65% | 9456800.00% | 0.00x | 1.03x | €17.27 Million |
| 2020 | 9.33% | 0.00% | 0.00x | 1.01x | €-18.77 Million |
| 2021 | 11.71% | 0.00% | 0.00x | 1.01x | €55.41 Million |
| 2022 | 4.86% | 1044901.09% | 0.00x | 1.05x | €-89.99 Million |
| 2023 | 4.91% | 0.00% | 0.00x | 1.07x | €-91.51 Million |
| 2024 | 4.90% | 679673.60% | 0.00x | 1.05x | €-93.94 Million |
Industry Comparison
This section compares Tubize-Fin's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $29,511,500
- Average return on equity (ROE) among peers: -113.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tubize-Fin (TUB) | €1.94 Billion | 47.23% | 0.00x | $4.28 Billion |
| EUROPEAN MEDICAL SOLUTIONS (ALEMS) | $9.89 Million | -7.17% | 3.42x | $49.45K |
| BioSenic S.A. (BIOS) | $2.38 Million | -535.12% | 9.56x | $1.37 Million |
| Celyad SA (CYAD) | $26.68 Million | -61.66% | 0.65x | $5.17 Million |
| Hyloris Developmentsen Sa (HYL) | $32.14 Million | -19.73% | 0.29x | $68.51 Million |
| Onward Medical N.V. (ONWD) | $-3.89 Million | 0.00% | 0.00x | $110.15 Million |
| Oxurion NV (OXUR) | $109.86 Million | -54.90% | 0.11x | $26.78K |